VANCOUVER, British Columbia, July 03, 2025 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. ("CLC" or the "Company") (CSE: CLC) announced today that it will not be filing its annual financial statements, accompanying management's discussion and analysis and related chief executive officer ("CEO") and chief financial officer ("CFO") certifications for the financial year ended February 28, 2025 (collectively, the "Annual Filings"), within the period prescribed for the filing of such documents under Parts 4, 5 and 6 of National Instrument 51-102 Continuous Disclosure Obligations and pursuant to National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, namely within 120 days of year-end, being June 30, 2025 (the "Filing Deadline").
OAKLAND, Calif., July 2, 2025 /PRNewswire/ --PG&E Corporation (NYSE: PCG) will hold a conference call on Thursday, July 31, 2025, at 11:00 a.m. Eastern...
SPRINGFIELD, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Greystone Real Estate Advisory Group (GREA), serving as transaction advisor for the Massachusetts Division of Capital Asset Management & Maintenance (DCAMM), is pleased to announce a Request for Proposals (RFP) which provides an exceptional opportunity to design, build, and own a landmark facility anchored by a 40-year initial lease with the Commonwealth -- a new courthouse facility in Springfield, MA.
Four-building, Class A industrial portfolio totals 2.04 million square feet in Manteca, California Located near major highways and an intermodal rail terminal, the properties...
Four-building, Class A industrial portfolio totals 2.04 million square feet in Manteca, California Located near major highways and an intermodal rail terminal, the properties...
Redesigned facility features 50,000 square feet of climate-controlled storage and offers a range of integrated services to serve semiconductor and aerospace customers
PHOENIX, July...
WINGHAM, ON, July 2, 2025 /CNW/ - Royal Homes Limited, Ontario's longest established housing manufacturer, has been acquired by a management group led by...
SEOUL, South Korea and SINGAPORE, July 2, 2025 /PRNewswire/ -- Empyrion Digital, a leading digital infrastructure platform in Asia, today announced the grand opening of...
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public offering of 2,482,692 shares of its common stock at a price to the public of $19.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,363,469 shares of its common stock at a price to the public of $19.4999, which represents the per share public offering price for the shares of common stock less $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to ArriVent from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $75 million. In addition, ArriVent has granted the underwriters a 30-day option to purchase up to an additional 576,923 shares of its common stock on the same terms and conditions. All of the securities are being offered by ArriVent.
Recent investments have strengthened the grid and reduced outages for customersThe electric utility serves nearly 680,000 customers in the Upstate region and along the...